Skip to main content
Top
Published in: Journal of Gastroenterology 1/2024

19-10-2023 | Helicobacter Pylori | Original Article—Alimentary Tract

Clinicopathologic differences of gastric neoplasms between Helicobacter pylori-infected and -naïve patients: a multicenter retrospective analysis

Authors: Satoshi Kotani, Kotaro Shibagaki, Noriyuki Hirahara, Nobuaki Hasegawa, Ryo Tanabe, Yuri Ebisutani, Saya Nonomura, Kenichi Kishimoto, Yasuhide Kodama, Yusuke Takahashi, Masatoshi Kataoka, Akihiko Oka, Nobuhiko Fukuba, Yoshiyuki Mishima, Naoki Oshima, Kousaku Kawashima, Norihisa Ishimura, Asuka Araki, Kyuichi Kadota, Ayako Itawaki, Makoto Nagasaki, Yoichi Miyaoka, Hideyuki Onuma, Shunji Ishihara

Published in: Journal of Gastroenterology | Issue 1/2024

Login to get access

Abstract

Background

The incidence of gastric neoplasms in Helicobacter pylori (Hp)-naïve patients has recently increased due to a remarkable decrease in the Hp-infected population in Japan. We investigated the clinicopathologic differences between Hp-infected gastric neoplasms (HpIGNs) and Hp-naïve gastric neoplasms (HpNGNs) that have not been fully elucidated so far.

Methods

This retrospective multicenter study investigated 966 consecutive patients with 1131 gastric dysplasia or cancers who underwent endoscopic or surgical treatment for the recent decade. Clinicopathologic features were compared between HpIGN and HpNGN cases.

Results

One thousand and sixty-eight HpIGNs in 916 patients included 877 differentiated types and 191 undifferentiated types. Sixty-three HpNGNs in 50 patients included 57 differentiated types (35 foveolar types, 15 intestinal types, 6 fundic-gland types, and 1 other differentiated type) and 6 undifferentiated types. HpNGNs occurred in younger (59.5 vs. 71.8 years, p < 0.05) and female patients (40.0% vs. 26.5%, p < 0.05), were found more frequently in the proximal compartment (p < 0.05), and had smaller size (median 4.0 vs. 20.0 mm, p < 0.05). Histologically, HpNGNs and HpIGNs both primarily consisted of differentiated type (90.5% vs. 82.1%, p = 0.089) and HpNGNs showed lower prevalence of invasive cancer (11.1% vs. 37.6%, p < 0.05) and lymphovascular invasion (1.6% vs. 31.6%, p < 0.05). Nearly all HpNGNs (62/63, 98.4%) were diagnosed in early pathological stage, while 16.1% (172/1068) of HpIGNs were diagnosed in advanced stage (p < 0.05).

Conclusions

HpNGNs is recently on the increase but shows lower malignant nature regardless of histologic type than HpIGN. Endoscopic gastric cancer screening will be reviewed via cost effectiveness for Hp-naïve individuals in future.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gawron AJ, Shah SC, Altayar O, et al. AGA technical review on gastric intestinal metaplasia-natural history and clinical outcomes. Gastroenterology. 2020;158(705–31): e5. Gawron AJ, Shah SC, Altayar O, et al. AGA technical review on gastric intestinal metaplasia-natural history and clinical outcomes. Gastroenterology. 2020;158(705–31): e5.
2.
go back to reference Shibagaki K, Itawaki A, Miyaoka Y, et al. Intestinal-type gastric dysplasia in Helicobacter pylori-naive patients. Virchows Arch. 2022;480:783–92.PubMed Shibagaki K, Itawaki A, Miyaoka Y, et al. Intestinal-type gastric dysplasia in Helicobacter pylori-naive patients. Virchows Arch. 2022;480:783–92.PubMed
3.
go back to reference Takita M, Ohata K, Inamoto R, et al. Endoscopic and histological features of Helicobacter pylori-negative differentiated gastric adenocarcinoma arising in the antrum. JGH Open. 2021;5:470–7.PubMedPubMedCentral Takita M, Ohata K, Inamoto R, et al. Endoscopic and histological features of Helicobacter pylori-negative differentiated gastric adenocarcinoma arising in the antrum. JGH Open. 2021;5:470–7.PubMedPubMedCentral
4.
go back to reference Akazawa Y, Ueyama H, Hayashi T, et al. Clinicopathological and molecular characterization of early gastric adenocarcinoma in Helicobacter pylori-uninfected patients: emphasis on differentiated gastric adenocarcinoma. J Gastroenterol. 2022;57:725–34.PubMed Akazawa Y, Ueyama H, Hayashi T, et al. Clinicopathological and molecular characterization of early gastric adenocarcinoma in Helicobacter pylori-uninfected patients: emphasis on differentiated gastric adenocarcinoma. J Gastroenterol. 2022;57:725–34.PubMed
5.
go back to reference Shibagaki K, Mishiro T, Fukuyama C, et al. Sporadic foveolar-type gastric adenoma with a raspberry-like appearance in Helicobacter pylori-naive patients. Virchows Arch. 2021;479:687–95.PubMed Shibagaki K, Mishiro T, Fukuyama C, et al. Sporadic foveolar-type gastric adenoma with a raspberry-like appearance in Helicobacter pylori-naive patients. Virchows Arch. 2021;479:687–95.PubMed
6.
go back to reference Ueyama H, Yao T, Nakashima Y, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34:609–19.PubMed Ueyama H, Yao T, Nakashima Y, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34:609–19.PubMed
7.
go back to reference Yamada A, Kaise M, Inoshita N, et al. Characterization of Helicobacter pylori-naive early gastric cancers. Digestion. 2018;98:127–34.PubMed Yamada A, Kaise M, Inoshita N, et al. Characterization of Helicobacter pylori-naive early gastric cancers. Digestion. 2018;98:127–34.PubMed
8.
go back to reference Yamamoto Y, Fujisaki J, Omae M, et al. Helicobacter pylori-negative gastric cancer: characteristics and endoscopic findings. Dig Endosc. 2015;27:551–61.PubMed Yamamoto Y, Fujisaki J, Omae M, et al. Helicobacter pylori-negative gastric cancer: characteristics and endoscopic findings. Dig Endosc. 2015;27:551–61.PubMed
9.
go back to reference Tumor of the stomach. In: Digestive system tumors WHO classification of tumors editorial board (Eds) Digestive system tumors teWP, Geneva pp59–104. Tumor of the stomach. In: Digestive system tumors WHO classification of tumors editorial board (Eds) Digestive system tumors teWP, Geneva pp59–104.
10.
go back to reference Kakinoki R, Kushima R, Matsubara A, et al. Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. DGDAis Sci. 2009;54:614–20. Kakinoki R, Kushima R, Matsubara A, et al. Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. DGDAis Sci. 2009;54:614–20.
11.
go back to reference Kato S, Matsukura N, Tsukada K, et al. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci. 2007;98:790–4.PubMed Kato S, Matsukura N, Tsukada K, et al. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci. 2007;98:790–4.PubMed
12.
go back to reference Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–9.PubMed Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–9.PubMed
13.
go back to reference Ono S, Kato M, Suzuki M, et al. Frequency of Helicobacter pylori -negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion. 2012;86:59–65.PubMed Ono S, Kato M, Suzuki M, et al. Frequency of Helicobacter pylori -negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion. 2012;86:59–65.PubMed
14.
go back to reference Inoue M. Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer. 2017;20:3–7.PubMed Inoue M. Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer. 2017;20:3–7.PubMed
15.
go back to reference Nagy P, Johansson S, Molloy-Bland M. Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA. Gut Pathog. 2016;8:8.PubMedPubMedCentral Nagy P, Johansson S, Molloy-Bland M. Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA. Gut Pathog. 2016;8:8.PubMedPubMedCentral
16.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMed Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMed
17.
go back to reference Japanese classification of gastric carcinoma, October 2017 the 15th edition, Japanese gastric cancer association. Japanese classification of gastric carcinoma, October 2017 the 15th edition, Japanese gastric cancer association.
18.
go back to reference Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated sydney system. International workshop on the histopathology of gastritis houston. Am J Surg Pathol. 1996;20:1161–81.PubMed Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated sydney system. International workshop on the histopathology of gastritis houston. Am J Surg Pathol. 1996;20:1161–81.PubMed
19.
go back to reference Kishikawa H, Kimura K, Takarabe S, et al. Helicobacter pylori antibody titer and gastric cancer screening. Dis Markers. 2015;2015: 156719.PubMedPubMedCentral Kishikawa H, Kimura K, Takarabe S, et al. Helicobacter pylori antibody titer and gastric cancer screening. Dis Markers. 2015;2015: 156719.PubMedPubMedCentral
20.
go back to reference Mishiro T, Shibagaki K, Fukuyama C, et al. KLF4 mutation shapes pathologic characteristics of foveolar-type gastric adenoma in Helicobacter pylori-naive patients. Am J Pathol. 2022;192:1250–8.PubMed Mishiro T, Shibagaki K, Fukuyama C, et al. KLF4 mutation shapes pathologic characteristics of foveolar-type gastric adenoma in Helicobacter pylori-naive patients. Am J Pathol. 2022;192:1250–8.PubMed
21.
go back to reference Naka T, Hashimoto T, Cho H, et al. Sporadic and familial adenomatous polyposis-associated foveolar-type adenoma of the stomach. Am J Surg Pathol. 2023;47:91–101.PubMed Naka T, Hashimoto T, Cho H, et al. Sporadic and familial adenomatous polyposis-associated foveolar-type adenoma of the stomach. Am J Surg Pathol. 2023;47:91–101.PubMed
22.
go back to reference Valente P, Garrido M, Gullo I, et al. Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggressiveness. Gastric Cancer. 2015;18:720–8.PubMed Valente P, Garrido M, Gullo I, et al. Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggressiveness. Gastric Cancer. 2015;18:720–8.PubMed
23.
go back to reference Sugai T, Uesugi N, Habano W, et al. The clinicopathological and molecular features of sporadic gastric foveolar type neoplasia. Virchows Arch. 2020;477:835–44.PubMedPubMedCentral Sugai T, Uesugi N, Habano W, et al. The clinicopathological and molecular features of sporadic gastric foveolar type neoplasia. Virchows Arch. 2020;477:835–44.PubMedPubMedCentral
24.
go back to reference Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.
25.
go back to reference Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.PubMed Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.PubMed
26.
go back to reference Yorita N, Ito M, Boda T, et al. Potential of Helicobacter pylori-uninfected signet ring cell carcinoma to invade the submucosal layer. J Gastroenterol Hepatol. 2019;34:1955–62.PubMed Yorita N, Ito M, Boda T, et al. Potential of Helicobacter pylori-uninfected signet ring cell carcinoma to invade the submucosal layer. J Gastroenterol Hepatol. 2019;34:1955–62.PubMed
27.
go back to reference Iwamuro M, Kusumoto C, Nakagawa M, et al. Endoscopic features of oxyntic gland adenoma and gastric adenocarcinoma of the fundic gland type differ between patients with and without Helicobacter pylori infection: a retrospective observational study. BMC Gastroenterol. 2022;22:294.PubMedPubMedCentral Iwamuro M, Kusumoto C, Nakagawa M, et al. Endoscopic features of oxyntic gland adenoma and gastric adenocarcinoma of the fundic gland type differ between patients with and without Helicobacter pylori infection: a retrospective observational study. BMC Gastroenterol. 2022;22:294.PubMedPubMedCentral
29.
go back to reference Gawron AJ, Shah SC, Altayar O, et al. AGA technical review on gastric intestinal metaplasia-natural history and clinical outcomes. Gastroenterology. 2020;158:705–31.PubMed Gawron AJ, Shah SC, Altayar O, et al. AGA technical review on gastric intestinal metaplasia-natural history and clinical outcomes. Gastroenterology. 2020;158:705–31.PubMed
30.
go back to reference Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 2008;44:2397–403.PubMed Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 2008;44:2397–403.PubMed
31.
go back to reference Jang YC, Leung CY, Huang HL. Association of hormone replacement therapy with risk of gastric cancer: a systematic review and meta-analysis. Sci Rep. 2022;12:12997.PubMedPubMedCentral Jang YC, Leung CY, Huang HL. Association of hormone replacement therapy with risk of gastric cancer: a systematic review and meta-analysis. Sci Rep. 2022;12:12997.PubMedPubMedCentral
32.
go back to reference D’Elia L, Rossi G, Ippolito R, et al. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr. 2012;31:489–98.PubMed D’Elia L, Rossi G, Ippolito R, et al. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr. 2012;31:489–98.PubMed
33.
go back to reference La Torre G, Chiaradia G, Gianfagna F, et al. Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years. Tumori. 2009;95:13–22.PubMed La Torre G, Chiaradia G, Gianfagna F, et al. Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years. Tumori. 2009;95:13–22.PubMed
34.
go back to reference Shin CM, Kim N, Cho SI, et al. Association between alcohol intake and risk for gastric cancer with regard to ALDH2 genotype in the Korean population. Int J Epidemiol. 2011;40:1047–55.PubMed Shin CM, Kim N, Cho SI, et al. Association between alcohol intake and risk for gastric cancer with regard to ALDH2 genotype in the Korean population. Int J Epidemiol. 2011;40:1047–55.PubMed
35.
go back to reference Horiuchi Y, Fujisaki J, Ishizuka N, et al. Study on clinical factors involved in Helicobacter pylori-uninfected undifferentiated-type early gastric cancer. Digestion. 2017;96:213–9.PubMed Horiuchi Y, Fujisaki J, Ishizuka N, et al. Study on clinical factors involved in Helicobacter pylori-uninfected undifferentiated-type early gastric cancer. Digestion. 2017;96:213–9.PubMed
37.
go back to reference Horiuchi Y, Fujisaki J, Yamamoto N, et al. Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer: comparison with Helicobacter pylori-positive early gastric cancer. Gastric Cancer. 2016;19:160–5.PubMed Horiuchi Y, Fujisaki J, Yamamoto N, et al. Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer: comparison with Helicobacter pylori-positive early gastric cancer. Gastric Cancer. 2016;19:160–5.PubMed
38.
go back to reference Okano A, Kato S, Ohana M. Helicobacter pylori-negative gastric cancer: advanced-stage undifferentiated adenocarcinoma located in the pyloric gland area. Clin J Gastroenterol. 2017;10:13–7.PubMed Okano A, Kato S, Ohana M. Helicobacter pylori-negative gastric cancer: advanced-stage undifferentiated adenocarcinoma located in the pyloric gland area. Clin J Gastroenterol. 2017;10:13–7.PubMed
39.
go back to reference Takagi A, Ozawa H, Oki M, et al. Helicobacter pylori-negative advanced gastric cancer with massive eosinophilia. Intern Med. 2018;57:1715–8.PubMedPubMedCentral Takagi A, Ozawa H, Oki M, et al. Helicobacter pylori-negative advanced gastric cancer with massive eosinophilia. Intern Med. 2018;57:1715–8.PubMedPubMedCentral
40.
go back to reference Sekine S, Yoshida H, Jansen M, et al. The Japanese viewpoint on the histopathology of early gastric cancer. Adv Exp Med Biol. 2016;908:331–46.PubMed Sekine S, Yoshida H, Jansen M, et al. The Japanese viewpoint on the histopathology of early gastric cancer. Adv Exp Med Biol. 2016;908:331–46.PubMed
41.
go back to reference Koseki K, Takizawa T, Koike M, et al. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer. 2000;89:724–32.PubMed Koseki K, Takizawa T, Koike M, et al. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer. 2000;89:724–32.PubMed
42.
go back to reference Ueyama H, Yao T, Akazawa Y, et al. Gastric epithelial neoplasm of fundic-gland mucosa lineage: proposal for a new classification in association with gastric adenocarcinoma of fundic-gland type. J Gastroenterol. 2021;56:814–28.PubMedPubMedCentral Ueyama H, Yao T, Akazawa Y, et al. Gastric epithelial neoplasm of fundic-gland mucosa lineage: proposal for a new classification in association with gastric adenocarcinoma of fundic-gland type. J Gastroenterol. 2021;56:814–28.PubMedPubMedCentral
43.
go back to reference Hamashima C, Ogoshi K, Narisawa R, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol. 2015;21:2460–6.PubMedPubMedCentral Hamashima C, Ogoshi K, Narisawa R, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol. 2015;21:2460–6.PubMedPubMedCentral
44.
go back to reference Matsumoto S, Yoshida Y. Efficacy of endoscopic screening in an isolated island: a case-control study. Indian J Gastroenterol. 2014;33:46–9.PubMed Matsumoto S, Yoshida Y. Efficacy of endoscopic screening in an isolated island: a case-control study. Indian J Gastroenterol. 2014;33:46–9.PubMed
45.
go back to reference Azuma T, Yamazaki S, Yamakawa A, et al. Association between diversity in the Src homology 2 domain–containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer. J Infect Dis. 2004;189:820–7.PubMed Azuma T, Yamazaki S, Yamakawa A, et al. Association between diversity in the Src homology 2 domain–containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer. J Infect Dis. 2004;189:820–7.PubMed
46.
go back to reference Yoda Y, Takeshima H, Niwa T, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer. 2015;18:65–76.PubMed Yoda Y, Takeshima H, Niwa T, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer. 2015;18:65–76.PubMed
47.
go back to reference Nikaido M, Kakiuchi N, Miyamoto S, et al. Indolent feature of Helicobacter pylori-uninfected intramucosal signet ring cell carcinomas with CDH1 mutations. Gastric Cancer. 2021;24:1102–14.PubMed Nikaido M, Kakiuchi N, Miyamoto S, et al. Indolent feature of Helicobacter pylori-uninfected intramucosal signet ring cell carcinomas with CDH1 mutations. Gastric Cancer. 2021;24:1102–14.PubMed
48.
go back to reference Namikawa K, Tanaka N, Ota Y, et al. Genomic features of Helicobacter pylori-naive diffuse-type gastric cancer. J Pathol. 2022;258:300–11.PubMedPubMedCentral Namikawa K, Tanaka N, Ota Y, et al. Genomic features of Helicobacter pylori-naive diffuse-type gastric cancer. J Pathol. 2022;258:300–11.PubMedPubMedCentral
49.
go back to reference Maeda M, Takeshima H, Iida N, et al. Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3. Gut. 2020;69:243–51.PubMed Maeda M, Takeshima H, Iida N, et al. Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3. Gut. 2020;69:243–51.PubMed
Metadata
Title
Clinicopathologic differences of gastric neoplasms between Helicobacter pylori-infected and -naïve patients: a multicenter retrospective analysis
Authors
Satoshi Kotani
Kotaro Shibagaki
Noriyuki Hirahara
Nobuaki Hasegawa
Ryo Tanabe
Yuri Ebisutani
Saya Nonomura
Kenichi Kishimoto
Yasuhide Kodama
Yusuke Takahashi
Masatoshi Kataoka
Akihiko Oka
Nobuhiko Fukuba
Yoshiyuki Mishima
Naoki Oshima
Kousaku Kawashima
Norihisa Ishimura
Asuka Araki
Kyuichi Kadota
Ayako Itawaki
Makoto Nagasaki
Yoichi Miyaoka
Hideyuki Onuma
Shunji Ishihara
Publication date
19-10-2023
Publisher
Springer Nature Singapore
Published in
Journal of Gastroenterology / Issue 1/2024
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-023-02050-2

Other articles of this Issue 1/2024

Journal of Gastroenterology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine